Dawnrays Pharmaceutical (02348) said its profit attributable to owners of the parent for the six months ended 30 June 2016 dropped 14.8% year-on-year to Rmb131 million.
Basic and diluted earnings per share were Rmb16.38 cents and Rmb16.36 cents.
The revenue was Rmb418 million, a decrease of 14.4% from a year earlier.
Gross profit slid 16% year-on-year to Rmb256 million. Gross profit margin was 61.1%, which was decreased by 1.2 percentage points compared with 62.3% as in the corresponding period of last year.
The proposed interim dividend is HK3 cents (2015: HK3 cents) per share, payable on or about 28 September 2016.
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情
